an il12-il2-antibody fusion protein targeting hodgkins lymphoma cells potentiates activation of nk and t cells for an anti-tumor attack一个il12-il2-antibody融合蛋白定位霍奇金淋巴瘤细胞强化激活nk细胞和t细胞的抗肿瘤攻击.pdfVIP

An IL12-IL2-Antibody Fusion Protein Targeting Hodgkin’s Lymphoma Cells Potentiates Activation of NK and T cells for an Anti-Tumor Attack . . ¨ Tobias Jahn , Martin Zuther , Bjorn Friedrichs, Claudia Heuser, Stefan Guhlke, Hinrich Abken, Andreas A. Hombach* Department I of Internal Medicine and Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany Abstract Successful immunotherapy of Hodgkin’s disease is so far hampered by the striking unresponsiveness of lymphoma infiltrating immune cells. To mobilize both adoptive and innate immune cells for an anti-tumor attack we fused the pro- inflammatory cytokines IL2 and IL12 to an anti-CD30 scFv antibody in a dual cytokine fusion protein to accumulate both cytokines at the malignant CD30+ Hodgkin/Reed-Sternberg cells in the lymphoma lesion. The tumor-targeted IL12-IL2 fusion protein was superior in activating resting T cells to amplify and secrete pro-inflammatory cytokines compared to targeted IL2 or IL12 alone. NK cells were also activated by the dual cytokine protein to secrete IFN-c and to lyse target cells. The tumor-targeted IL12-IL2, when applied by i.v. injection to immune-competent mice with established antigen-positive tumors, accumulated at the tumor site and induced tumor regression. Data demonstrate that simultaneous targeting of two cytokines in a spatial and temporal simultaneous fashion to pre-defined tissues is feasible by a dual-cytokine antibody fusion protein. In the case of IL12 and IL2, this produced superior anti-tumor efficacy implying the strategy to muster a broader immune cell response in the combat against cancer. Citation: Jahn T, Zuther M, Friedrichs B, Heuser C, Guhlke S, et al. (2012) An IL12-IL2-Antibody Fusion Protein Targeting Hodg